Serum lnc-DC and SOCS1 can be used as potential indicators for diagnosis and prognosis prediction of patients with systemic lupus erythematosus

Xiangnan Dong,Rui Cao,Lianghong Yin
2020-01-01
Abstract:This study aimed to investigate the diagnostic and prognostic value of serum lnc-DC and SOCS1 in patients with systemic lupus erythematosus (SLE). A total of 130 SLE patients admitted to the First Affiliated Hospital of Jinan University, were selected as SLE group, which were divided into active phase (n=78) and stationary phase (n=52). Meanwhile, 125 healthy persons who underwent physical examination at the same time were selected as control group (CG), and their clinical related indexes (C-reactive protein (CRP), complement C3, C4, anti-ds-DNA antibody (Anti-ds-DNA), immunoglobulin G (IgG), ESR, activity index (SLEDAI) score of systemic lupus erythematosus and correlation were detected. The serum lnc-DC and SOCS1 expression levels in SLE were dramatically lower than those in CG (P < 0.05), and the two in active patients in SLE group were dramatically lower than those in stable patients (P < 0.05). They can be used to diagnose SLE and distinguish active and stationary phases of SLE patients. Pearson analysis revealed that they were positively correlated with C3 and C4 of SLE patients, and obviously negatively correlated with IgG, CRP, ESR, Anti-ds-DNA and SLEDAI scores. After follow-up investigation, 39 SLE patients relapsed, with a relapse rate of 30.00%. The serum lnc-DC and SOCS1 of relapse patients were markedly lower than those of patients without relapse (P < 0.05). Those can be used to predict the recurrence of prognosis. Pearson analysis showed that serum lnc-DC and SOCS1 were remarkably positively correlated in active and stable SLE patients (P < 0.001). lnc-DC and SOCS1 are correlated in SLE, which can be used as biomarkers for diagnosis and prognosis prediction. And they have high research value in clinical practice.
What problem does this paper attempt to address?